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Abstract
The cytoplasmic domains of EGF-like ligands, including EGF cytoplasmic domain (EGFcyt), have important biological
functions. Using specific constructs and peptides of human EGF cytoplasmic domain, we demonstrate that EGFcyt
facilitates lysosomal and proteasomal protein degradation, and this coincided with growth inhibition of human
thyroid and glioma carcinoma cells. EGFcyt and exon 22-23–encoded peptide (EGF22.23) enhanced procathepsin B
(procathB) expression and procathB-mediated lysosomal degradation of EGFR/ErbB1 as determined by inhibitors
for procathB and the lysosomal ATPase inhibitor BafA1. Presence of mbEGFctF, EGFcyt, EGF22.23, and exon 23–
encoded peptides suppressed the expression of the deubiqitinating enzyme ubiquitin C-terminal hydrolase-L1
(UCH-L1). This coincided with hyperubiquitination of total cellular proteins and ErbB1/2 and reduced proteasome ac-
tivity. Upon small interfering RNA–mediated silencing of endogenously expressed UCH-L1, a similar hyperubiquitiny-
lation phenotype, reduced ErbB1/2 content, and attenuated growth was observed. The exon 23–encoded peptide
region of EGFcyt was important for these biologic actions. Structural homology modeling of human EGFcyt showed
that this molecular region formed an exposed surface loop. Peptides derived from this EGFcyt loop structure may aid
in the design of novel peptide therapeutics aimed at inhibiting growth of cancer cells.
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Introduction
Members of the family of epidermal growth factor (EGF)–like ligands
are synthesized as membrane-anchored proforms and are enzymatically
cleaved to release extracellular and intracellular domains. The inter-
action of the extracellular part of EGF-like ligands with the membrane-
bound EGF receptors, ErbB1-4, is well established and regulates normal
growth, differentiation, and tumorigenesis [1]. The important roles of the
cytoplasmic domain (cyt) of EGF-like ligands are emerging. The cyt
domains of transforming growth factor α (TGFα-cyt) and amphiregulin
(ARcyt) are important for cell polarity, intracellular vesicular trafficking
[2–5], and basolateral sorting [6–8]. Soluble neuregulin-1 cyt acts as a
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nuclear transcriptional suppressor for several regulators of apoptosis
[9,10], and its interaction with cytosolic LIM–kinase 1 is implicated
in visual-spatial cognition [9,11]. Heparin binding–epidermal growth
factor (HB-EGF)cyt can affect cell survival [12] and induces S-phase
entry by interacting with the cyclin A transcriptional repressor promye-
locytic leukemia zinc finger protein and its heterodimerization partner
B-cell lymphoma 6 [13–15]. Nuclear localization of HB-EGFcyt
is linked to aggressive transitional cell carcinoma [16]. Membrane-
anchored betacellulin (BTC) undergoes intramembrane processing by
presenilin 1 and/or presenilin 2–dependent gamma secretase to gener-
ate a free BTCcyt fragment that becomes palmitoylated as a prerequisite
for gamma secretase–dependent processing and nuclear membrane lo-
calization of BTCcyt [17]. Impaired basolateral sorting of pro-EGF
and inadequate renal EGFR activation caused by the P1070L mutation
in human proEGFcyt results in rare autosomal recessive renal hypo-
magnesemia syndrome [18]. Transgenic (tg) mice overexpressing
human proEGFcyt showed stunted growth [19]. In human thyroid
carcinoma cells, EGFcyt alters the acetylation state of the microtubules
and inhibits tumor cell invasion into elastin matrix by a reduced ex-
pression of (pro)cathepsin-L and impaired SNAP25-mediated process
of vesicle-membrane fusion [20,21].
Ligand-dependent ErbB receptor degradation involves the binding
of exogenous EGF to the EGFR (ErbB1), which triggers membrane-
anchored surface receptor phosphorylation and initiates EGFR inter-
nalization/degradation along the endolysosomal pathway [22,23].
Lysosomal hydrolases of the cathepsin family proteolytically process
EGFR [24], with procathepsin B (procathB) playing a major role in
EGFR degradation [25,26]. ErbB degradation also involves the ubiquitin-
proteasome system (UPS). UPS malfunction can increase the levels of
activated ErbB1/EGFR and ErbB2/Neu antigen, and this may con-
tribute to carcinogenesis [27,28]. Ubiquitination, the conjugation of
a highly conserved 76-amino-acid ubiquitin (Ub) molecule to a sub-
strate, is an energy-dependent multistep process [29]. Monoubiquitinin
signal will target ErbB receptors for endosomal degradation, whereas a
polyubiquitination tag is believed to mark the receptors for proteasomal
degradation [30,31]. Before proteasomal degradation, deubiquitination
enzymes (DUBs), including ubiquitin C-terminal hydrolase UCH-L1
and Ub-specific processing proteases (UBPs), cleave and recycle free Ub
from its ubiquitinated substrate [32]. UCH-L1 maintains intracellular
levels of free ubiquitin UCH-L1, and this preserves normal proteasome
function [33]. UCH-L1 is expressed in mature neurons and testicular
stem cells and is present during early embryogenesis [34]. Overexpres-
sion of UCH-L1 is found in numerous cancers and is correlated with
advanced stages of disease and poor prognosis for patient survival [35].
In the present study, we demonstrate two novel roles of EGFcyt as
an inducer of lysosomal procathB expression and a silencer of UCH-
L1 expression in human thyroid and glioma cancer cells. Both events
resulted in a decrease in cellular ErbB1/EGFR and ErbB2/Neu recep-
tor levels and reduced cancer cell growth. This function was critically
dependent on the presence of the exon 23–encoded peptide. Molec-
ular modeling showed that this exon 23–encoded domain formed a
loop structure in human EGFcyt.
Materials and Methods
Cell Culture
Human follicular thyroid carcinoma cell line FTC-133 and the
human glioma cell line LN-18 were cultured in HAM-F12 medium
(Fisher, Ottawa, Ontario, Canada) and 10% fetal calf serum (Sigma,
Oakville, Ontario, Canada). Stable transfectants of the follicular
thyroid carcinoma cell line FTC-133 harboring pcDNA4/HisMaxC
empty plasmid control or pcDNA4/HisMaxC containing constructs
encoding for the complete human EGF cytoplasmic domain (exons
22-24; EGFcyt), EGFcyt encoding for exon 22 and 23 (EGF22.23),
a natural splice version of EGFcyt lacking exon 23 (EGFdel23) [20],
and the human EGF, juxtamembrane, transmembrane, and cyto-
plasmic domain with C-terminal FLAG epitope (mbEGFctF; gift from
Dr S. Wiley) [36] (Figure 1A) were described previously [19–21].
Transient transfectants of the human glioma cell line LN-18 were gen-
erated by using effectin (Qiagen, Toronto, Ontario, Canada) and using
0.4 μg of EGF constructs and empty vector (mock control). Protein
lysates were harvested 48 hours after transient transfection for Western
blot analysis.
RNA Isolations and Reverse Transcription–Polymerase
Chain Reaction
Total RNA of all transfectants was isolated with TRIzol reagent (Life
Technologies, Burlington, Ontario, Canada), and RNA amounts
were determined by spectrophotometry at 260 and 280 nm. Total
RNA (1 μg) was used for first-strand complementary DNA (cDNA)
synthesis using the SuperScript reverse transcriptase kit and 500 ng/ml
of oligo d(T) primer (both Life Technologies). For reverse transcription–
polymerase chain reaction (RT-PCR), 1 μl of cDNA and 25 pM of
specific forward and reverse primer were used (Table 1). The PCR cycle
profile consisted of an initial denaturation at 95°C for 15 minutes fol-
lowed by 30 cycles of denaturation at 95°C for 1 minute, annealing at
60°C for 1 minute, and elongation at 72°C for 2 minutes. A negative
control devoid of cDNA template was included. Single-PCR products
were separated in a 1% agarose gel in TAE buffer (EMD, San Diego,
CA), visualized by ethidium bromide staining, and sequenced to
confirm identity.
Immunohistochemistry
Five-micrometer sections of paraformaldehyde-fixed and paraffin-
embedded human thyroid tissues were treated with 3% hydrogen
peroxidase to block endogenous peroxidase activity. Nonspecific bind-
ing were blocked with 3% bovine serum albumin and 10% goat
normal serum (Sigma). The sections were incubated with a rabbit poly-
clonal antiserum against UCH-L1 (1:100; Enzo Biochem, New York,
NY) overnight at 4°C. Sections were washed 3 × 10 in Tris (pH 7.4)
and 0.1% Tween 20 buffer and incubated with a secondary goat anti-
rabbit antibody (1:200; New England Bio [NEB], Ipswich, MA) for
1 hour at room temperature. Staining was developed using the DAB
kit (Pierce, Nepean, Ontario, Canada).
RNA Silencing
Mock and EGF23del transfectants at 60% confluence were trans-
fected with 50 nM siRNA-UCHL-1 (AM51331, s105082, ID7345) or
the nonsilencing scrambled sequence (5′AATTCTCCGAACGTGTCA-
CGT3′) as a control (both Ambion, Austin, TX) using Lipofectamine
2000 (Life Technologies). After 48 and 96 hours, UCH-L1 gene ex-
pression and UCH-L1 protein levels were assessed by RT-PCR and
Western blot analysis, respectively.
BrdU Proliferation Assay
Stable and transient transfectants were seeded at 103 cells/well into
96-well plates and cultured overnight in serum-free medium. Cells were
preincubated with exogenous EGF (10 ng/ml) for 8 hours and with
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Figure 1. (A) Schematic representation of human EGF constructs used in this study: cyt cytoplasmic domain; e22-24, exons 22 to 24;
JR, juxtamembrane region; TM, transmembrane domain. (B) Western blot analysis revealed an exclusive up-regulation of procathB in
stable human thyroid carcinoma transfectants expressing EGFcyt and EGF22.23. Deletion of the exon 23–encoded peptide region in
EGFdel23 and membrane-bound mbEGFctF failed to show an induction of procathB expression. (C) Treatment with specific inhibitors
for procathB/L (ZFF-FMK, 10 μM), cathB (CA-74-ME, 10 μM), and lysosomal ATPases (Baf-A1, 1 μM) resulted in enhanced EGFR protein
levels in the presence of EGFcyt and EGF22.23 (not shown) but failed to alter procathB and EGFR protein levels in mock. (D) Western
blot detection revealed an up-regulation of EGFR in the presence of ZFF-FMK (10 μM) in EGFcyt but not in mbEGFctF and mock trans-
fectants. Addition of exogenous EGF did not oppose the ZFF-FMK effect nor did EGF alter cellular EGFR protein levels. (E) Exclusive
expression of procathB protein in EGFcyt thyroid transfectants. Addition of exogenous EGF did not oppose the ZFF-FMK effect nor did
EGF alter procathB protein levels. (F) BrdU proliferation assays revealed increased proliferation of proEGFcyt and mock cells on EGF
treatment (10 ng/ml). The inhibitors ZFF-FMK (10 μM) and Baf-A1 (1 μM) did not alter cell growth nor did they interfere with the EGF-
induced proliferation.
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specific inhibitors. BrdU assays were performed according to the man-
ufacturer’s protocol (Roche, Mississauga, Ontario, Canada). Reactions
were stopped using 1 M H2SO4, and the absorbance was measured in
an ELISA reader at 450 nm.
Inhibitors
For BrdU assays and Western blots, cells were incubated with pro-
teasome inhibitors MG132 (10 μM) or lactacystine (1 μM) for 2 hours
and with cath-B inhibitor ZFF-FMK (10 μM), cath-B/-L inhibitor
CA-74-ME (10 μM), and the inhibitor of lysosomal ATPases BafA1
(1 μM) for 3 hours (all Calbiochem, San Diego, CA) and ErBb1 inhib-
itor AG1478 (10 μM) for 1 hour (Sigma-Aldrich, Oakville, Ontario,
Canada). Batimastat (Sigma-Aldrich) was used as described earlier [36].
Cellular proteins were extracted with 1× Laemmli buffer (4% SDS,
Tris-HCl pH 7.6, mercaptoethanol, bromophenol blue).
MTT Cell Viability Assay
Cells were seeded at 103 cells/well into 96-well plates and cultured
overnight in serum-free medium. Cells were incubated with specific
inhibitors to determine their cytotoxicity effect on cells.MTT assays were
performed according to the manufacturer’s protocol (Life Technologies).
Transient Transfection with EGFcyt Peptides
Parental FTC-133 cells were transfected with N-terminally fluo-
rescein isothiocyanate (FITC)–labeled 10- to 12-mer synthetic peptides
(EZBioLab, Carmel, IN) derived from the exon 22– and exon 23–
encoding peptide sequences of human EGFcyt using the Chariot kit
according to manufacturer’s instructions (Ambion; Table 2). Trans-
fection efficiency was consistently more than 70% as determined by
counting FITC-positive cells in a Z1 upright fluorescent microscope
(Zeiss, Jena, Germany).
Subcellular Fractionation and Western Blot Analysis
Cells were seeded in 25-cm2 flasks for 3 days under normal serum
conditions. At 80% confluence, cell protein lysates were taken using
a nuclear, cytoplasmic, and membrane extraction kit according to the
company protocol (Pierce). For Western blot, transfectants were
seeded at 8.5 × 104 cells/6 wells for 24 hours in serum-free medium
with and without treatment of MG132 and lactacystine (both at 1 μM).
For Western blot analysis, 20-μg/ml proteins were transferred onto a
Hybond nitrocellulose membrane (Thermo Scientific, Nepean, Ontario,
Canada) and nonspecific binding sites were saturated for 1 hour at room
temperature in blocking buffer containing Tris-buffered saline/0.01%
Tween 20 plus 5% skimmed milk. Membranes were incubated over-
night at 4°C with rabbit polyclonal antibodies to UCHL-1 (1:1000;
Enzo Biochem), histone 1 (H1), ErbB1, ErbB1Tyr1045, and ErB2 (all
1:1000; NEB), and a monoclonal antibody (mAb) to ubiquitin
(1:2000; Enzo Biochem), respectively. All antibodies were diluted in
blocking buffer. A mouse mAb against β-actin (1:20,000; Sigma) was
used to determine equal protein loading per lane. On incubation with
a horseradish peroxidase–conjugated goat anti-rabbit (1:2000; NEB) or
goat antimouse secondary antibody (1:20,000; Sigma) for 2 hours at
room temperature, specific immunoreactive bands were detected with
an ECL kit (Thermo Scientific, Nepean, Ontario, Canada).
Immunoprecipitation
FTC-133-EGFcyt, FTC-133-mbEGFctF, and corresponding
mock transfectants (1 × 106 cells) were harvested at 80% confluence,
lysed in 400 μl of lysis buffer (50 mM HEPES [pH 7.4], 1% Triton
X-100, 100 mM NaCl, 10 mM NaF, 1 mM EDTA, 1 mM sodium
vanadate) for 1 hour on ice and centrifuged at 13,000g for 15 minutes
at 4°C. Anti-EGFR antibody (10 μg/ml; Santa Cruz, Santa Cruz, CA)
was added in lysis buffer and incubated overnight at 4°C. Immuno-
complexes were purified by protein A/G agarose beads (30 μl/200 μl;
Sigma) with gentle rocking for 4 hours at 4°C, pelleted for 60 seconds,
and washed 3× in 500 μl of ice-cold lysis buffer. Pellets were resus-
pended twice in 100 μl of 3× SDS sample buffer (1.25 M Tris, pH 6.8,
10% SDS, 20% glycerol, 10% mercapthoethanol, 2% bromophenol
blue), heated to 90°C for 5 minutes followed byWestern blot detection
of immunoprecipitated EGFR (1:1000, NEB). Membranes were
stripped with buffer containing 0.2 M glycine and 0.05 Tween 20
for 15 minutes at room temperature, washed, blocked with 5% milk,
and probed for c-Cbl (1:1000; Santa Cruz) and ubiquitin (Ub; 1:2000)
(Cedarlane, Burlington, Ontario, Canada).
Proteasome Activity Assay
Transfectants expressing cytosolic EGFcyt, mbEGFctF, and mock
cells were seeded in 96-well plates at 1 × 103 cells/well. Cells were
pretreated with 10 μM of MG132 for 1 hour and soluble EGF for
8 hours (10 ng/ml). Proteasomal activity assays were performed accord-
ing to the manufacturer’s protocol (Promega, Madison, WI).
Homology Modeling of the EGFcyt Domain
The homology modeling approach was used to generate 3D struc-
tures of EGFcyt composed of 149 amino acids [37]. The Modeller
Web-based server was used in model building. On the basis of sequence
identity values ranging between 35% and 38%, the structure of the
receptor binding protein P2 of PRD1 (PDB code: 1n7v) was used as
one of the templates. The strain energy of the model was generated
Table 1. Primer Sequences Used for the Amplification of Target Genes Listed.
Target Primer Primer Sequence (from 5′ to 3′)
UCHL-1 Forward CCC CGA GAT GCT GAA CAA AGT G GGG
Reverse CTG CCT GTA TGG CCT CA
UCHL-3 Forward GCT GGA GGC CAA TCC CGA GG
Reverse GGT ATC TGG CTC GTT CTT CAG G
EGFR Forward TGT GAG GTG GTC CTT GGG AAT TTG G
Reverse TGC TGA CTA TGT CCC GCC ACT GGA
EGFcyt Forward ACTCAGAAGCTGCTATCGAAAAACCC
Reverse CTCACTGAGTCAGCTCCATTTGGTG
ErbB2 Forward GAA CCC CCA GCT CTG CTA CCA
Reverse CGT AGA AAG GTA GTT GTA GGG AC
GAPDH Forward CATCACCATCTTCTAGGACCG
Reverse TGACCTTGCCCACAGCCTTG
Table 2. Peptide Sequences Used in This Study.
EGFcyt Coding Region of Peptides Peptide No. Peptide Sequence (N′- to C′-terminus)
Exon 22 P1 TQKLLSKNPKNP
P2 KNPYEESSRDVR
P3 DVRSRRPADTED
P4 TEDGMSSCPQP
Exon 23 P1 PQPWFVVIKE
P2 VIKEHQDLKN
P3 DLKNGGQPVA
P4 QPVAGEDGQAAD
Scrambled peptide P5 QPVIHDGVAAE
Peptides (10-12 mer) were designed to cover the complete exons 22 and 23 and have a three amino
acid overlap at the N-terminus with each consecutive C-terminal peptide. All peptides were FITC
conjugated at the N-terminus to monitor cellular uptake.
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separately in the GROMOS force field using the 53A6 parameter set
optimized for molecular dynamic simulations. After building the 3D
model of human EGFcyt, all atomic positions were locked, and re-
quired hydrogen atoms were added to the backbone structure of the
molecule. Molecular dynamics simulation was performed at 1 × 106 for
50 picoseconds for further optimization in GROMACS (version 3.3).
This involved a brief, steepest-descent run that used a maximum step
protocol of 1.5 Å, and a maximum tolerance of 2000 kJ/mol per nano-
meter followed by a more extensive conjugate gradient minimization
with tolerances of 200 kJ/mol per nanometer. After building and refine-
ment of the 3D EGFcyt model, the Protein Structure &Model Assess-
ment Tools were used to verify the quality of the model. This tool is
capable of verifying a number of aspects of model qualities such as (i)
local model quality estimation (anolea atomic mean force potential, em-
pirical force field, composite scoring function for model quality estima-
tion), (ii) global model quality estimation (all atom distance–dependent
statistical potential), (iii) stereochemistry check (protein structure veri-
fication, stereochemical quality check; minimum resolution, 2.5 Å),
and (iv) structural features (secondary structure, geometrical features,
and solvent exposure assignment, analysis of protein structure motifs).
On the basis of these assessment results, model quality was evaluated
according to the Ramachandran plot and the amino acid residues in the
allowed, disallowed region and overall G factor.
Statistical Analysis
All experiments were repeated at least three times for two different
clones. For multiple experiment comparisons, analysis of variance table
and Tukey test were used with P < .05 considered significant.
Figure 2. (A, C) In thyroid cancer cells, EGFcyt and EGF22.23 caused a 50% decrease in proliferation when compared to EGFdel23 and
mock. Treatment with exogenous EGF (10 ng/ml), MG132 (10 μM), and lactacystine (1 μM) either completely or partially antagonized the
growth inhibitory action of EGFcyt and EGF22.23, respectively. Dual treatment of cells with exogenous EGF plus MG132 or lactacystine
(1 μM) showed that the proteasome inhibitor did not antagonize the growth-promoting action of EGF. (B and D) MbEGFctF had no
growth-inhibitory effect and treatments with EGF (10 ng/ml) MG132 (10 μM) and lactacystine (1 μM) failed to affect cell proliferation
in mbEGFctF and mock cells.
400 ProEGFcyt in ErbB Receptor Degradation Glogowska et al. Neoplasia Vol. 14, No. 5, 2012
Results
EGFcyt Affects Cathepsin-B–Mediated EGFR Degradation
in Cancer Cells
Cathepsin-B (cathB) plays an important role in the lysosomal deg-
radation of EGFR [26]. Here we demonstrate that of all EGF
constructs tested (Figure 1A), soluble EGFcyt and EGF22.23 up-
regulated procathB in thyroid cancer (Figure 1B) and glioma cells
(Figure W1A). This effect was not observed with membrane-
anchored mbEGFctF, the EGFdel23 splice variant with a deletion
of exon 23, or mock cells (Figures 1B and W1A), suggesting cellular
compartment-specific EGFcyt effects and a functional role for the
EGFcyt exon 23 peptide region. Both immunoreactive cathB and
CD63 were colocalized in mock and EGFcyt clones, indicating lyso-
somal localization of procathB (data not shown). The presence of
EGFcyt coincided with diminished EGFR and ErbB2 expression in
stably transfected thyroid cancer cells (Figures 1C and 6, A and B) and
transiently transfected LN-18 glioma cells (Figure W1B). To deter-
mine an involvement of lysosomal procathB in this EGFR down-
regulation, EGFcyt thyroid transfectants and mock were incubated
with specific inhibitors for cathB (ZFF-FMK, 10 μM), cathL/B
(CA-74-ME, 10 μM), or the inhibitor of lysosomal ATPases BafA1
(1 μM). Treatment with these three inhibitors resulted in a marked
up-regulation of EGFR in the EGFcyt transfectants but not in mock
(Figure 1C ). ZFF-FMK also caused the up-regulation of EGFR in
EGFcyt glioma transfectants (Figure W1C ). However, in mbEGFctF
and mock transfectants cellular levels of EGFR (Figures 1D and
W1C ) and procathB (Figures 1E and W1D) remained unchanged.
The EGFR present in the thyroid (Figure W4, B-D) and EGFcyt
glioma (Figures W1E andW3) transfectants was bioactive in response
to exogenous EGF and caused a maximal proliferative response similar
to mock, whereas BafA1 and ZFF-FMK alone had no effect on pro-
liferation (Figures 1F and W1E ).
EGFcyt Affects Proteasome Activity in Cancer Cells
We determined the ability of structurally distinct EGFcyt domains
to affect the proliferation of human thyroid and brain cancer cells.
Cancer cells expressing soluble EGFcyt and EGF22.23 showed
significantly reduced BrdU incorporation when compared with mock
and/or EGFdel23 (Figure 2A) and mbEGFctF (Figures 2B and
Figure 3. (A and B) Proteasome activity was significantly decreased in the presence of EGFcyt and, to a lesser extent, in mbEGFctF
clones when compared to the corresponding mock. EGF-mediated EGFR activation and the inhibition thereof by EGFR inhibitor AG1478
had no effect on proteasomal activity in these cells. Despite attenuated proteasome activity in the presence of EGFcyt and EGF22.23,
proteasome activity in all clones investigated was inhibited at 1 μM of MG132. (A and C) The same results were obtained with
mbEGFctF, suggesting a similar mechanism by which EGFcyt, EGF22.23, andmbEGFctF can decrease proteasome activity. These results
also emphasized the importance of the exon 23–encoded peptide region in this process because EGFdel23 and mock failed to affect
proteasome activity.
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W2A) transfectants. This reduction in cancer cell growth was not the
result of increased cell death as determined by cytotoxicity assays (data
not shown). EGF-induced EGFR activation antagonized the growth
inhibitory effect of EGFcyt in thyroid cancer (Figures 2, A and C ,
and W4, A and B) and glioma (Figure W3) cells. Treatment of mock,
EGFdel23, and mbEGFctF clones with soluble EGF caused a small
increase in cell proliferation (Figures 2, A-D, W3, and W4, A and
B). We determined if cleavage of the extracellular EGF part of
mbEGFctF may account for the increased proliferation of mbEGFctF
clones compared with EGFcyt transfectants. BrdU proliferation assays
in the presence of the matrix metalloproteinase (MMP) inhibitor
batimastat failed to alter the proliferation of mbEGFctF in thyroid
transfectants, indicating that the increased proliferation observed in
mbEGFctF clones was not a result of liberation of EGF from the
mbEGFctF protein with subsequent EGFR activation (Figure W4A).
However, batimastat was able to decrease the proliferation of LN-18,
suggesting EGFR activation as a result of proteolytic release of endog-
enous EGF-like ligand(s) in these glioma cells. We detected the expres-
sion of endogenous proEGF by PCR in LN-18 cells (data not shown).
The decrease in proliferation with batimastat was significant in EGFcyt
and mbEGFctF LN-18 transfectant but not in the mock controls
(Figure W3).
The proteasome inhibitors MG132 and lactacystine increased EGFR
levels in thyroid cancer cells (Figure 6B) and glioma (Figure W2B) and
enhance growth rates of EGFcyt and EGF22.23 transfectants (Figure 2,
A andC ).We detected a significant reduction in proteasomal activity in
the presence of EGFcyt and EGF22.23 (Figure 3, A and B) and, to a
lesser extent, in mbEGFctF (Figure 3, A and C). Proteasomal activity
assays in the presence of increasing concentrations of MG132 con-
firmed the inhibitory effect of EGFcyt, EGF22.23 (Figure 3B) and
mbEGFctF (Figure 3C ) and indicated similar inhibition kinetics.
Almost complete proteasomal inhibition was observed at 1 μM MG132
in all transfectants (Figure 3, B and C). Treatment with soluble EGF
and/or the EGFR inhibitor AG1478 failed to increase proteasomal
activity in EGFcyt clones (Figure 3A). Cytotoxicity assays done in
the presence of MG132, lactacystine, and EGF confirmed that the
Figure 4. (A) UCH-L1 gene activity and (B) UCH-L1 protein were exclusively downregulated in the presence of EGFcyt, EGF22.23, and
mbEGFctF. (C) Specific 10- to 12-mer peptides covering the complete EGFcyt peptide region encoded by exons 22 and 23 were used to
determine the specificity of exon-derived peptides for the silencing of UCH-L1 by EGFcyt. Exclusively peptides encoded by the exon 23–
derived peptide sequences of EGFcyt, but not scrambled peptides or peptides derived from pEGFcyt exon 22, were capable of downregu-
lating UCH-L1 expression at the gene and protein levels. Representative immunodetection of UCH-L1 in (D) papillary and (E) undifferentiated
human thyroid cancer tissues. (F and G) No specific immunostaining was detected in normal human thyroid tissues (data not shown) and
when the primary antiserum was replaced by a species-specific nonimmune serum at the same concentration. Magnification, ×20.
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Figure 5. (A) Representative Western blots showing the level of ubiquitinated proteins in EGFcyt and mock cells. In the presence of
EGFcyt and mbEGFctF, the level of ubiquitinated total protein and protein fractions derived from subcellular compartments was in-
creased. This enhanced protein ubiquitination was not observed with EGFdel23 (not shown) and mock. Ponceau S–stained blots served
as loading control. EGFR served as marker for the membrane fraction, β-actin for the total and cytoplasmic fraction and histone 1 (H1) as
marker for the nuclear fraction. (B) Transfection with a specific siUCH-L1 (50 nM) construct for 72 and 96 hours successfully silenced
UCH-L1 expression in UCH-L1+ mock cells. (C) Western blot analysis showed that silencing of UCH-L1 protein coincided with increased
levels of total ubiquitinated (Ub−) proteins in siUCH-L1 treated mock compared with UCH-L1+ mock and UCH-L1− EGFcyt cells treated
with scrambled siRNA.
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reduction of proteasomal activity in the EGFcyt clones was not the
result of increased cell death (data not shown).
EGFcyt Is a Novel Regulator of UCH-L1 in Cancer Cells
Microarray analysis identified and subsequent RT-PCR andWestern
blot data identified ubiquitin C-terminal hydrolase (UCH-L1) as a tar-
get gene in thyroid cancer cells. Thyroid cancer transfectants express-
ing EGFcyt and EGF22.23 showed the silencing of UCH-L1 at the
mRNA (Figure 4A) and protein levels (Figure 4B). In the presence
of mbEGFctF, UCH-L1 gene expression was attenuated at the mRNA
(Figure 4A) and protein levels (Figure 4B). Treatment with soluble
EGF for up to 4 hours did not change UCH-L1 protein levels in the
EGFcyt and mbEGFctF clones (Figure 4B). LN-18 glioma cells
showed strong UCH-L1 expression, but transient transfection with
EGFcyt or mbEGFctF caused markedly reduced UCHL-1 protein lev-
els (Figure W2C). UCH-L1 down-regulation by EGFcyt, EGF22.23,
and mbEGfctF was specific for UCH-L1 and not observed for UCH-
L3 in glioma (data not shown) and thyroid cancer cells (Figure 4A).
UCH-L1 is a member of the DUB protein family and plays an
important role in the processing of Ub as part of protein degradation.
To identify particular peptide regions in the EGFcyt domain responsi-
ble for this down-regulation of UCH-L1, we used FITC-labeled 10- to
12-mer peptides that covered the entire exon 22 and exon 23 region
of human EGFcyt (Table 2). Thyroid cells were transfected with the
different FITC-peptide conjugates, and transfection efficiency was
determined in each case to be at 60% to 70% (counted fraction of
FITC-stained to unstained cells). All peptides derived from the exon
23 peptide region caused a complete loss of UCH-L1 protein, whereas all
exon 22–encoded peptides and the scrambled control peptide failed to af-
fect UCH-L1 expression (Figure 4C). Thus, the exon 23–encoded peptide
region of the human EGF cytoplasmic domain, as a membrane-bound
Figure 6. (A) Although RT-PCR did not show a difference in ErbB1
and ErbB2 gene expression (data not shown), Western blot analysis
revealed a decrease of ErbB1 and ErbB2 protein in the presence of
EGFcyt and EGF22.23. No change in ErbB status was detected in
the presence ofmbEGFctF, EGFdel23, andmock. (B) Treatmentwith
the proteasome inhibitors MG132 and lactacystine increased the
amount of ErbB1 and ErbB2 protein in EGFcyt and mbEGFctF trans-
fectants as shown in representative Western blots. Proteasome
inhibitors had no effect on ErbB1/2 protein levels in EGFdel23 (data
not shown) and mock transfectants. Equal protein loading was
assessed by detecting β-actin.
Figure 7. (A) UCH-L1 siRNA treatment (50 nM) successfully silenced
endogenous UCH-L1 expression in mock. MG132 (10 μM) treat-
ment did not influence silencing of UCH-L1 in mock cells. (B) On
UCH-L1 knockdown, Western blot analysis showed reduced ErbB1
and ErbB2 protein levels. However, in mock treated simultaneously
with MG132 (10 μM) and siUCH-L1 (50 nM), this receptor down-
regulation was abolished, suggesting that proteasome activity
was essential for the degradation of ubiquitinated ErbB1/2. β-Actin
was used to assess equal protein loading. (C) Silencing of UCH-L1
gene activity in mock resulted in an approximately 50% reduction in
proliferation, which was similar to the growth rates determined for
UCH-L1–negative EGFcyt transfectants.
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or soluble form, was identified to have an essential role in suppressing
UCH-L1 expression in cancer cells.
The expression of UCH-L1 in human thyroid tissues has not been
reported. We performed immunohistochemistry and demonstrated,
for the first time, the presence of immunoreactive UCH-L1 in human
papillary (Figure 4D) and undifferentiated (Figure 4E ) thyroid carci-
noma tissues. Normal human thyroid tissue (not shown) and control
sections with primary antiserum replaced by nonimmune serum were
devoid of UCH-L1 (Figure 4, F and G ). Our results suggest the
exclusive expression of UCH-L1 in thyroid cancer tissues.
EGFcyt Decreases UCH-L1, Causes Hyperubiquitination of
Cellular Proteins, and Reduces ErbB1/2 Receptor Levels
Cells with impaired UCH-L1–mediated DUB function are known
to show high levels of protein ubiquitination [38]. Western blot
analysis of total, cytoplasmic, nuclear, and membrane-bound protein
Figure 8. (A) Western blot detection of total fractions of EGFR and c-Cbl plus/minus treatment with EGF before IP; β-actin was used to
assess equal protein loading. IP experiments and subsequent Western blot analysis confirmed the attenuated EGFR levels in the pres-
ence of EGFcyt. Unstimulated EGFcyt cells revealed enhanced levels of ubiquitinated EGFR similar to mock treated with EGF. In the
presence of EGFcyt, coimmunoprecipitation of c-Cbl with EGFR revealed reduced c-Cbl–EGFR interaction compared with mock, which
increased markedly on EGF treatment. An IgG1a isotype control antibody was used as a negative control in the IP experiments. (B) West-
ern blot detection of total fractions of EGFR and c-Cbl plus/minus treatment with EGF before IP; β-actin was used to assess equal protein
loading. IP results for EGFR, c-Cbl and ubiquitinated EGFR in mbEGFctF and mock cells plus/minus EGF treatment showed comparable
results. Treatment with exogenous EGF caused phosphorylation of EGFR at residue Tyr1045 (see Figure W4, C and D) and enhanced the
interaction between c-Cbl and activated EGFR in all transfectants studied. An IgG1a isotype control antibody was used as a negative
control in the IP experiments. (C) A structural model of human EGFcyt was generated based on the structure of the receptor binding
protein P2 of PRD1 (PDB code: 1n7v) used as template. This molecule has up to 38% amino acids identity with human EGFcyt. The
exon 23–encoded peptide region marked in red was found to form an exposed loop.
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fractions showed increased levels of ubiquitinated cellular proteins in
the presence of either EGFcyt or mbEGFctF (Figure 5A). RT-PCR and
Western blot analysis confirmed the successful specific knockdown of
UCH-L1 for more than 96 hours in UCH-L1–positive EGFdel23
and mock clones (Figure 5B). Silencing of UCH-L1 resulted in signifi-
cantly elevated levels of ubiquitinated proteins at 72 and 96 hours in
mock transfectants (Figure 5C). Next, we addressed if a reduced level of
UCH-L1 can affect the level of ErbB receptors, particularly ErbB1/
EGFR and ErbB2/Neu antigen, and whether this may contribute to
the attenuated cell growth in the presence of EGFcyt. We failed to de-
tect changes in ErbB1 gene expression in any of the transfectants inves-
tigated (data not shown) but observed a significant decrease in ErbB1
and ErbB2 protein content exclusively in the presence of EGFcyt (and
EGF22.23) in thyroid cancer cells (Figure 6, A and B) and glioma
transfectants (Figure W1B). No change in ErbB1/2 protein content
was detectable in mbEGFctF, EGFdel23, or mock cells (Figures 6,
A and B, and W1B). Treatment with proteasome inhibitors MG132
and lactacystine resulted in increased ErbB1/2 protein levels exclusively
in proEGFcyt and mbEGFctF transfectants (Figures 6B and W2B).
Upon si-UCH-L1 treatment, we detected decreased levels of UCH-L1
mRNA (data not shown), UCH-L1 protein (Figure 7, A and B) and
ErbB1/2 protein (Figure 7B). Treatment with MG132 failed to affect
UCH-L1 levels in siUCH-L1–treated cells (Figure 7A) but abolished
the siUCH-L1–induced decrease in ErbB1/2 (Figure 7B), resulting
in protein levels similar to untreated and si-control–treated mock
(Figure 7, A and B). The siUCH-L1–treated mock cells with a de-
crease in ErbB1/2 levels showed significantly reduced cell prolif-
eration (Figure 7C ). We performed immunoprecipitation (IP) assays
with a specific antibody to EGFR on mock and UCH-L1–negative
EGFcyt thyroid transfectants plus/minus EGF treatment to determine
whether the presence of EGFcyt coincided with the increased level of
ubiquitinated EGFR. Irrespective of EGF treatment, the IP revealed
attenuated total EGFR protein levels in EGFcyt clones compared with
mock (Figure 8A). Ubiquitinated EGFR was clearly observed in un-
treated EGFcyt transfectants but only weakly detectable in mock
(Figure 8A). In mock, but not in EGFcyt transfectants, EGF treatment
resulted in an increased presence of ubiquitinated EGFR (Figure 8A).
IP results for mbEGFcyt and mock transfectants show similar EGFR
levels, and in both cases, we observed an increase in ubiquitinated
EGFR on EGF treatment (Figure 8B). When the anti-EGFR was re-
placed by a nonimmune IgG1a control serum, no immunoprecipitated
proteins were detected (Figure 8, A and B). In all transfectants investi-
gated, EGF treatment caused a marked increase in the phosphorylation
of EGFR tyrosine residue 1045 (EGFR-Tyr1045) (Figure W4C ),
which was inhibited in the presence of the EGFR inhibitor AG1478
(Figure W4D). We performed co-IP experiments for c-Cbl, known
to ubiquitinate [22,39,40] EGFR-Tyr1045 [41] and assist in the sorting
process of the EGFR [42]. EGF treatment resulted in significantly
increased c-Cbl coimmunoprecipitation with EGFR in mock, EGFcyt
(Figure 8A), and mbEGFctF clones (Figure 8B).
Rendered Structural Modeling Reveals an Exposed
Exon 23–Encoded Peptide Loop in EGFcyt
The molecular structure of human EGFcyt has not been reported.
We used homology modeling based on the receptor binding protein
P2 of PRD1 (PDB code: 1n7v), a modeling template displaying up
to 38% amino acid identity with human EGFcyt. The rendered
model of the cytoplasmic domain of human EGF revealed the exon
23–encoded peptide region we identified as a biologically important
molecular module of EGFcyt to form an exposed loop structure po-
tentially capable of participating in protein interactions involving
EGFcyt (Figure 8C ).
Discussion
In the present study, we identified soluble EGFcyt as a novel factor
affecting lysosomal (pro)cathB–mediated degradation and proteasomal
activity in cancer cells. We had previously demonstrated the presence of
soluble human EGFcyt in the cytoplasm of cancer cells [19,20]. The
increased procathB expression and down-regulation in EGFR protein
were dependent on the exon 23–encoded peptide region present in
EGFcyt and EGF22.23, confirming our previous findings of the im-
portant role of this peptide region as an essential molecular determinant
for the in vitro and in vivo biologic activity of the EGF cytoplasmic do-
main [19–21]. CathB has been recognized as an important and specific
degradation mechanism for EGFR in the endolysosomal compartment
[26]. EGF ligand–mediated activation results in monoubiquitination at
multiple sites within the tyrosine activation domain of EGFR [30,43],
which serves as a signal for receptor internalization [30,44,45] and reg-
ulates sorting of endosomal EGFR to lysosomes [46,47]. Continuous
EGFR ubiquitination by the E3 ubiquitin ligase c-Cbl is required for
lysosomal targeting and degradation of the EGFR [42,48]. The specific
inhibition of cathB and the elevation of the acidic pH in the endosomal-
lysosomal compartment by the vacuolar-type ATPase (V-ATPase) in-
hibitor bafilomycin A1 (BafA1), known to disrupt the vesicular proton
gradient and raise the pH of acidic vesicles [49], effectively blocked
EGFR degradation in the presence of EGFcyt in cancer cells.
The presence of soluble and membrane-anchored EGFcyt and
EGF22.23, all containing the exon 23–encoded peptide region, was
also associated with reduced proteasome activity which could be
further suppressed with increasing concentrations of MG132, a non-
selective proteasome inhibitor known to also inhibit procathB [50].
To discriminate between these two inhibitory effects, we replaced
MG132 with the selective proteasome inhibitor lactacystine [51]
but obtained similar results. We identified the deubiquitin esterase
UCH-L1, a major cellular ubiquitin hydrolase [33], as a novel tran-
scriptional target that was specifically downregulated or completely
silenced in the presence of mbEGFctF and EGFcyt, respectively.
Intriguingly, the silencing of UCH-L1 was also achieved using small
peptides designed according to the exon 23–encoded peptide
sequence of EGFcyt. UCH-L1 is involved in diverse aspects of tumor
cell adhesion and motility [52,53], but its role in tumor cell growth is
still unclear and may depend on the specific cell context [54–57].
Uch-L1 transgenic mice recently provided conclusive evidence for a
role of UCH-L1 as an oncogene. These mice displayed a high inci-
dence of sporadic tumors, primarily consisting of lymphomas and
lung adenoma [52]. In humans, prostate cancer is among numerous
cancers shown to express UCH-L1 [58]. Here we provide evidence for
the presence of UCH-L1 in human thyroid carcinoma. UCH-L1 was
absent in normal thyroid tissues, suggesting that UCH-L1 may qualify
as a novel marker for thyroid cancer cells.
Proper control of cellular ubiquitin levels is crucial for normal cell
functions and requires the balanced actions of ubiquitin ligases and
DUB enzymes [47,59–61]. Malfunction of the ubiquitin pathway due
to UCH-L1 depletion in the presence of proEGFcyt, proEGF22.23,
and exon23 peptides or UCH-L1 decrease in mbEGFctF clones coin-
cided with increased ubiquitination of total, cytoplasmic, membrane,
and nuclear protein fractions, including EGFR. This likely triggered
a depletion of the cellular pool of free ubiquitin that caused the decrease
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in proteasome activity observed in thyroid cancer cells [33,62,63]. Fur-
thermore, the UCH-L1negative, procathBhigh EGFcyt phenotype re-
sulted in lysosomal degradation of ErbB1/2 receptors as determined
by our cathB/lysosomal inhibitor studies and significantly reduced cell
growth in our cancer cell models. Importantly and contrary to human
fibroblasts from patients with eight different lysosomal storage diseases,
the attenuated UCH-L1 expression in our cancer cell models was not
associated with increased cell death [62].
EGFR-activating EGF-like ligands can antagonize the function of
EGFcyt [21]. We used the general MMP inhibitor batimastat to ac-
count for the possibility of a proteolytic release of (a) the bioactive
extracellular EGF part of the membrane-anchored mbEGFctF that
may stimulate EGFR (Figure 1A) [36] and/or (b) the MMP-mediated
cleavage of endogenous membrane-bound EGF-like ligands. Such
effects would explain differences observed between the EGFcyt and
mbEGFctF transfectants because a liberated EGF/endogenous
EGF-like ligand is expected to counteract the actions of the EGFcyt
domain. Although batimastat had no effect in thyroid transfectants, it
caused a small but significant decrease in proliferation with the glioma
EGFcyt and mbEGFctF clones. The fact that we detected endoge-
nous EGF expression in LN-18 may explain that both EGFcyt and
mbEGFctF clones showed similar responses to batimastat and made
proteolytic release of the EGF domain of the mbEGFctF construct
unlikely. In addition, the batimastat experiments clearly showed that
the release of endogenous EGF-like ligand had no significant effect on
the responses measured, suggesting that the cellular effects observed
for EGFcyt and mbEGFctF in thyroid and glioma cancer cells were
genuine and, in the case of LN-18, only marginally affected by en-
dogenously induced EGFR activity. Further support for a lack of
enzymatic processing of mbEGFctF or its involvement in juxtacrine ac-
tivation of EGFR on neighboring cells [36] came from the finding that
mbEGFctF and mock clones showed similar levels of c-Cbl–EGFR in-
teraction. The E3 ubiquitin ligase c-Cbl is known to ubiquitinate
EGFR [22,39,40] and assist in the sorting process of this tyrosine ki-
nase receptor [42]. As expected, the proto-oncogene and RING finger
member c-Cbl coimmunoprecipitated with ubiquitinylated EGFR
[42,64] and EGF-mediated EGFR phosphorylation caused the en-
hanced c-Cbl interactions with activated EGFR, suggesting that neither
membrane-anchored nor soluble EGFcyt interfered with the ligand-
induced c-Cbl–EGFR protein interaction.
This study demonstrated for the first time that EGFcyt can down-
regulate ErbB2/Neu. The ErbB2 receptor is commonly considered
an endocytosis-impaired receptor and ligand-activated EGFR-ErbB2
dimers largely recycle back to the cell membrane for reactivation
[65–67]. Despite its known association with the two E3 ubiquitin
ligases CHIP and c-Cbl [67–70], the impaired ability of ErbB2 to
undergo ubiquitination has been suggested as a potential cause [71].
Recently, the deubiquitinating activity of POH1, a component of
the 19S proteasomal lid, was shown to have a critical role in the regu-
lation of ubiquitinated ErbB2 levels [72]. We identified a novel role
of UCH-L1 in facilitating the EGFcyt-mediated down-regulation of
ErbB2, implicating UCH-L1 as an important novel DUB in EGF-
cyt-mediated regulation of both ErbB1 and ErbB2 [73].
Our data provide further evidence for a potential tumor suppressor
function of the small EGFcyt peptide region encoded by exon 23 in
cancer cells [19–21], and this involves UCH-L1. Our structural
homology modeling predicted this exon 23–encoded peptide region
to be an exposed loop structure accessible for protein-protein inter-
actions. The combination of existing ErbB inhibitors and the UCH-
L1 gene silencing effect of specific exon 23–encoded peptides may be
a novel attractive therapeutic strategy for the treatment of patients with
aggressive ErbB1/2–dependent cancers.
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Figure W1. (A) Western blot analysis revealed the up-regulation of procathB in human glioma cell line LN-18 transiently transfected with
EGFcyt. This effect was not observed with mbEGFctF construct. (B) Decreased EGFR and ErbB2 protein levels in LN-18 transiently
transfected with EGFcyt. This effect was not observed with mbEGFctF construct. (C) Western blot analysis revealed an up-regulation
of EGFR in the presence of ZFF-FMK (10 μM) in EGFcyt glioma transfectants. No change was observed in mbEGFctF transfectants and
mock. (D) The same ZFF-FMK treatment did not alter cellular procathB expression in any of the LN-18 clones. (E) BrdU proliferation
assays revealed decreased proliferation in LN-18 EGFcyt transfectants and treatment with the general MMP inhibitor batimastat caused
a significant decrease in proliferation in EGFcyt and mbEGFctF clones suggestive of a possible weak EGFR activation through cleaved
EGF-like ligand(s). In all cases, EGF treatment (10 ng/ml) caused a significant increase in proliferation in LN-18 EGFcyt clones. The
procathB inhibitor ZFF-FMK (10 μM) did not affect cell growth in the presence or absence of exogenous EGF.
Figure W2. (A) BrdU proliferation assays revealed a 12% increase
in proliferation in LN-18 EGFcyt transfectants on MG132 treat-
ment, which was enhanced further in the presence of EGF. The
general MMP inhibitor batimastat caused a small but significant
decrease in proliferation in LN-18 EGFcyt and mbEGFctF clones
suggestive of a possible weak EGFR activation through cleaved
EGF-like ligand(s). (B) Western blot analysis revealed an exclusive
up-regulation of EGFR in the presence of MG132 (10 μM) in LN-18
EGFcyt transfectants. No change was observed with mbEGFctF
transfectants and mock. (C) Representative Western blot demon-
strating that both EGFcyt and mbEGFctF glioma transfectants
showed reduced levels of cellular UCH-L1. β-Actin served as a
loading control.
Figure W3. BrdU proliferation assays showing the increased pro-
liferation in EGFcyt glioma transfectants and mock on EGF treat-
ment (10 ng/ml). The EGF-induced proliferation was blocked by the
EGFR inhibitor AG1478 (10 μM). AG1478 alone or in combination
with the MMP inhibitor batimastat failed to significantly affect
glioma cell growth.
Figure W4. (A) Treatment of EGF-responsive EGFcyt and mbEGFctF
thyroid transfectants with the general MMP inhibitor batimastat
and subsequent BrdU assays. The increased proliferation of the
mbEGFctF compared with EGFcyt transfectants was not the result
of EGFR activation due to the proteolytic release of the extracellular
bioactive EGF domain of the mbEGFctF construct. Batimastat failed
to cause a change in proliferation in any of the transfectants tested.
(B) The EGF-induced (10 ng/ml) increase in proliferation of EGFcyt,
mbEGFctF, and corresponding mock thyroid transfectants was
blocked by the EGFR inhibitor AG1478 (10 μM) as determined by
BrdU proliferation assays. AG1478 itself did not affect cell growth.
EGF treatment caused EGFcyt transfectants to significantly increase
their proliferation rate to reach growth rates similar to mock. (C)
Western blot detection of total EGFR and EGFR phosphorylated at
residue Tyr1045 (EGFR-Tyr1045) in thyroid EGFcyt, mbEGFctF, and
mock transfectants. EGF (10 ng/ml) caused the specific Tyr1045
phosphorylation of EGFR in all transfectants investigated. (D) EGFR
phosphorylation at residue Tyr1045 was completely blocked in the
presence of the specific EGFR inhibitor AG1478.
